Pacific Edge Limited ( ($NZ:PEB) ) just unveiled an update.
Pacific Edge reported a steep revenue decline in FY26 after losing U.S. Medicare coverage in April 2025, with operating revenue falling to $11.5 million and total Cxbladder test volumes down 16.3%, while its net loss widened to $35.8 million despite a nearly 10% reduction in expenses. The company strengthened its balance sheet with a NZ$25.4 million share placement and an up to NZ$6 million retail offer, reduced monthly cash burn and tightened its U.S. sales footprint to preserve capital.
Strategically, the year culminated in a draft Medicare Local Coverage Determination that, for the first time, recognises hematuria evaluation as a covered benefit and proposes coverage for Cxbladder Triage and the higher-priced Triage Plus, enabling claim-by-claim reimbursement and materially improving unit economics. Pacific Edge is now focused on shifting volume to higher-margin tests, leveraging new clinical evidence and EMR-integrated clinical pathways, expanding APAC adoption, and progressing its next-generation Surveillance Plus test, positioning the company for a return to growth and a clearer path to profitability in FY27 and beyond.
More about Pacific Edge Limited
Pacific Edge Limited is a New Zealand-based cancer diagnostics company listed on the NZX and ASX that develops and commercialises urine-based molecular tests for bladder cancer detection and monitoring. Its flagship Cxbladder suite, including Triage and Triage Plus, targets hematuria evaluation and surveillance, with a growing focus on the U.S. Medicare market, commercial payers and expansion across the Asia-Pacific region.
YTD Price Performance: 45.95%
Average Trading Volume: 890,514
Technical Sentiment Signal: Buy
Current Market Cap: N$316.4M
For detailed information about PEB stock, go to TipRanks’ Stock Analysis page.
